Recent examples

Brain in Hand

Information coming soon...

Certus Technology Associates Ltd

Certus Technology designs, builds, delivers and supports adaptable software and services, to assist higher education establishments, life-science, biotech, healthcare and private sector organisations in the management of complex data and processes. They are working with Dr. Matt Anderson on machine learning approaches for classifying and predicting disease progression trajectories in children with Duchenne Muscular Dystrophy (DMD). This has led to funding through the Big Data & Environmental Futures Impact Lab and their European Regional Development Fund award, and—along with David Whitehouse and Prof. Krasimira Tsaneva-Atanasova—to an application through Innovate UK for a Knowledge Transfer Partnership focussing on decision support systems based on disease and clinical care models.

First Databank

Information coming soon...

National Physical Laboratory

Dr. Cama (IRF) and Dr. Stefano Pagliara (Senior Lecturer, Biosciences) are collaborating with Dr. Maxim Ryadnov of the National Physical Laboratory on the development of novel peptide based antibiotics to overcome the current antibiotic resistance crisis. Drs. Cama and Pagliara are using their expertise in microfluidics to study the response of hundreds to thousands of individual bacteria to the new antibiotics via time-lapse microscopy, providing single-cell level phenotyping for the novel compounds produced by the Ryadnov group. The collaboration has led to the grant of a Pathway to Development (P2D) award, and the hire of a PDRA currently working at the LSI on this project.

RD&E – Inflammatory Bowel Disease Group

Following a successful clinical secondment for Dr. Simeng Lin with the TREE, the Inflammatory Bowel Disease (IBD) & Pharmacogenetics Group (Exeter Medical School, RD&E) are continuing their collaboration with Dr. Matt Anderson and Dr. Brandon Invergo. Led by Consultant Gastroenterologist, Dr. Nick Kennedy, their primary aim is to use machine learning and multi-omics approaches to identify clinically actionable factors that cause loss of drug response in IBD patients. They have recently applied for Wellcome Trust seed corn funding through the TREE as a primer for the next phase of their work.